New Class of Synthetic Polymer-Antibiotics Overcomes Antibiotic Resistance with Michele Dilizia Recce Pharmaceuticals

Published: July 6, 2020, 5:36 p.m.

Michele Dilizia, Executive Director of Regulatory Affairs and Microbiology, Recce Pharmaceuticals discusses why Recce is focused on developing a new class of broad spectrum synthetic polymer-antibiotics that can be used repeatedly against a wide range of bacteria without contributing to antibiotic resistance.\xa0 Michele also speaks to how Recce\xae 327, Recce's lead asset, is designed to empower doctors with a near universal treatment that can kill multiple types of bacteria in the blood, even superbugs, that can cause sepsis.

@ReccePharma

#antibioticresistance #syntheticantibodies #infections #superbugs #sepsis

Recce.com.au

Download the transcript here.